Mary Dejevsky

Could the Sputnik vaccine end Russia’s rift with the West?

Accounts differ. But it would appear that during a wide-ranging conference call earlier this week, the leaders of France and Germany broached the possibility of – wait for it – buying some of Russia’s pandemic pride and joy: its Sputnik V vaccine. If a deal is struck this would be a huge boost to Russia at home and abroad, and by extension to President Putin, who has spent months trying to dispel widespread Western suspicions about the Russian vaccine, from its Soviet-era name to the breakneck speed of its development.

Any deal would also represent quite a turnaround for France and Germany, whose leaders have spearheaded a Continental European reluctance to accept what many regard as ‘foreign’ vaccines in general and the Russian vaccine in particular. This in turn has fuelled a pervasive belief in Russia that Western misgivings have been grounded more in politics than in any scientific consideration of Sputnik’s merits. Russian regulators assess its efficacy at more than 91 per cent, which would place it among the most effective Covid-19 vaccines that have so far come to market.

Sputnik V attracted particular venom from the British media – not, perhaps, without some official prompting – which suggested that its science was slipshod, that the Russian laboratory had not conducted sufficient trials and even that the Salisbury poisonings had shown the malign purposes to which Russia put its science. When the team at the Gamaleya Centre of Russia’s Health Ministry managed to place an article in the Lancet – validation, finally, as Moscow saw it, from a mainstream international journal – what was seen in Russia as a small victory, was seen elsewhere as a questionable editorial decision.


Scepticism, even hostility, was not limited to the UK, even though Russia has a sound tradition of vaccine research, including at the Gamaleya Centre, where Sputnik V was developed.

Already a subscriber? Log in

Keep reading with a free trial

Subscribe and get your first month of online and app access for free. After that it’s just £1 a week.

There’s no commitment, you can cancel any time.

Or

Unlock more articles

REGISTER

Comments

Don't miss out

Join the conversation with other Spectator readers. Subscribe to leave a comment.

Already a subscriber? Log in